CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.23 HKD | -1.20% |
|
-1.56% | +13.20% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,101 | 3,372 | 4,241 | 5,064 | 4,992 | 5,767 | - | - |
| Enterprise Value (EV) 1 | 1,559 | -178.4 | 50.04 | 17.21 | 4,992 | -54.87 | -536.9 | -1,420 |
| P/E ratio | 10.3 x | 11.5 x | 7.59 x | 6.98 x | 5.16 x | 5.25 x | 4.54 x | 3.94 x |
| Yield | 3.49% | 7.16% | 6.95% | 4.77% | 6.36% | 7.43% | 8.68% | 9.86% |
| Capitalization / Revenue | 1.89 x | 1.27 x | 1.32 x | 1.28 x | 1.11 x | 1.1 x | 0.95 x | 0.82 x |
| EV / Revenue | 0.58 x | -0.07 x | 0.02 x | 0 x | 1.11 x | -0.01 x | -0.09 x | -0.2 x |
| EV / EBITDA | 2.03 x | -0.25 x | 0.06 x | 0.02 x | 3.79 x | -0.04 x | -0.34 x | -0.78 x |
| EV / FCF | - | - | - | - | 6.33 x | -0.1 x | -0.6 x | -1.04 x |
| FCF Yield | - | - | - | - | 15.8% | -969% | -168% | -96.3% |
| Price to Book | 0.89 x | 0.58 x | 0.72 x | 0.79 x | 0.71 x | 0.82 x | 0.75 x | 0.68 x |
| Nbr of stocks (in thousands) | 773,403 | 754,600 | 755,400 | 755,400 | 755,400 | 755,400 | - | - |
| Reference price 2 | 6.595 | 4.469 | 5.614 | 6.703 | 6.608 | 7.635 | 7.635 | 7.635 |
| Announcement Date | 3/31/20 | 3/30/21 | 3/29/22 | 3/30/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,706 | 2,656 | 3,224 | 3,951 | 4,517 | 5,239 | 6,056 | 7,002 |
| EBITDA 1 | 767.5 | 723.8 | 826 | 1,022 | 1,316 | 1,367 | 1,577 | 1,812 |
| EBIT 1 | 562.5 | 515.4 | 643.6 | 835.8 | 1,139 | 1,280 | 1,506 | 1,754 |
| Operating Margin | 20.79% | 19.41% | 19.97% | 21.16% | 25.21% | 24.43% | 24.87% | 25.05% |
| Earnings before Tax (EBT) 1 | 642.8 | 395 | 720.1 | 917 | 1,240 | 1,441 | 1,669 | 1,920 |
| Net income 1 | 503.2 | 295 | 556.7 | 722.8 | 969.5 | 1,129 | 1,308 | 1,505 |
| Net margin | 18.59% | 11.11% | 17.27% | 18.3% | 21.47% | 21.55% | 21.61% | 21.49% |
| EPS 2 | 0.6400 | 0.3900 | 0.7400 | 0.9600 | 1.280 | 1.453 | 1.682 | 1.936 |
| Free Cash Flow 1 | - | - | - | - | 788.3 | 532 | 900 | 1,367 |
| FCF margin | - | - | - | - | 17.45% | 10.15% | 14.86% | 19.52% |
| FCF Conversion (EBITDA) | - | - | - | - | 59.91% | 38.91% | 57.06% | 75.45% |
| FCF Conversion (Net income) | - | - | - | - | 81.31% | 47.11% | 68.79% | 90.86% |
| Dividend per Share 2 | 0.2300 | 0.3200 | 0.3900 | 0.3200 | 0.4200 | 0.5670 | 0.6630 | 0.7530 |
| Announcement Date | 3/31/20 | 3/30/21 | 3/29/22 | 3/30/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 Q1 |
|---|---|---|---|
| Net sales 1 | - | 2,118 | 1,118 |
| EBITDA | - | - | - |
| EBIT | - | 524.2 | - |
| Operating Margin | - | 24.75% | - |
| Earnings before Tax (EBT) | - | 569 | - |
| Net income | 491.5 | 478 | - |
| Net margin | - | 22.57% | - |
| EPS | 0.6500 | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 8/30/23 | 3/28/24 | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 3,541 | 3,551 | 4,191 | 5,046 | - | 5,822 | 6,304 | 7,187 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | 788 | 532 | 900 | 1,367 |
| ROE (net income / shareholders' equity) | 9.32% | 8.63% | 9.52% | 11.8% | 14.5% | 15.3% | 16.1% | 16.8% |
| ROA (Net income/ Total Assets) | 7.76% | 6.96% | 7.72% | - | 10.9% | 11.5% | 12.3% | 12.7% |
| Assets 1 | 6,481 | 4,237 | 7,209 | - | 8,903 | 9,836 | 10,663 | 11,884 |
| Book Value Per Share 2 | 7.400 | 7.660 | 7.810 | 8.450 | 9.310 | 9.290 | 10.20 | 11.20 |
| Cash Flow per Share | 0.4700 | - | 0.9300 | - | - | - | - | - |
| Capex 1 | 88.4 | 66 | 93.6 | - | 144 | 164 | 173 | 208 |
| Capex / Sales | 3.27% | 2.49% | 2.9% | - | 3.2% | 3.13% | 2.86% | 2.97% |
| Announcement Date | 3/31/20 | 3/30/21 | 3/29/22 | 3/30/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.635
CNY
Average target price
13.03
CNY
Spread / Average Target
+70.73%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +13.20% | 796M | |
| +19.64% | 43.3B | |
| +21.25% | 22.22B | |
| +18.92% | 15.43B | |
| +20.14% | 14.48B | |
| +53.19% | 12.72B | |
| -0.05% | 6.79B | |
| -11.11% | 6.71B | |
| -8.87% | 5.73B | |
| +14.68% | 5.5B |
- Stock Market
- Equities
- 2877 Stock
- Financials China Shineway Pharmaceutical Group Limited
